Pelias Mary Kay
GenELSI Consulting, Inc., New Orleans, LA 70118, USA.
Community Genet. 2006;9(2):73-7. doi: 10.1159/000091483.
The protection of human subjects in biomedical research has become a source of increasing concern over the past century. During the early days of human experimentation, the human subject was rarely if ever consulted about his or her participation in research because scientists and physicians acted in the traditional paternalistic role with respect to their subjects and patients. However, as options for both researchers and their subjects increased, more attention was focused on the rights and obligations of participants on both sides of the research relationship. Investigators became more aware of the costs and benefits associated with their research programs, and subjects became more curious about the nature of research and what could be reasonably expected from their participation. This paper reviews the evolution of the doctrine of informed consent in biomedical research and the development of rules and guidelines for the conduct of research in the United States, for the benefit of both researchers and their human subjects.
在过去的一个世纪里,生物医学研究中对人类受试者的保护已成为日益受到关注的一个问题。在人类实验的早期,很少会就个人参与研究一事向受试者进行咨询,因为科学家和医生对其受试者及患者扮演着传统的家长式角色。然而,随着研究人员及其受试者的选择增多,更多的注意力集中在了研究关系双方参与者的权利和义务上。研究人员更加意识到与其研究项目相关的成本和收益,而受试者则对研究的性质以及他们的参与可以合理期待的结果更加好奇。本文回顾了生物医学研究中知情同意原则的演变以及美国研究行为规则和指南的发展,以造福研究人员及其人类受试者。